Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial
about
Cytomegalovirus Infection May Contribute to the Reduced Immune Function, Growth, Development, and Health of HIV-Exposed, Uninfected African ChildrenThe March towards a Vaccine for Congenital CMV: Rationale and Models.The history of vaccination against cytomegalovirus.Cytomegalovirus Vaccines: Current Status and Future Prospects.DNA Vaccines: Recent Developments and the Future.Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.Cytomegalovirus (CMV) seroprevalence in the adult population of Germany
P2860
Q26742161-A61A9433-2B3B-4E8E-92D7-113336678354Q35920807-E8A3BB4B-DD10-41FD-9138-D001DBD47A84Q38384533-C6EC71AD-DBA5-4EAB-85EE-84A569F7F979Q38791353-AA50B40C-F64D-4269-9D29-53968CBFE5CDQ45892465-17DCBA4B-C725-4ADE-98AA-A1F6C9787993Q47546281-CC27476C-18F6-40C9-B50A-B1FBE19213E7Q56927429-14A81AC5-489C-4FB0-8B26-C19564699705
P2860
Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@ast
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@en
type
label
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@ast
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@en
prefLabel
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@ast
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@en
P2093
P2860
P356
P1433
P1476
Clinical Development of a Cyto ...... ncept to Pivotal Phase 3 Trial
@en
P2093
Alain P Rolland
Jennifer A Chaplin
Larry R Smith
Mary K Wloch
Michele Gerber
P2860
P304
P356
10.3390/VACCINES1040398
P577
2013-09-25T00:00:00Z